Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Mar 19;108(5):1092–1099. doi: 10.1038/bjc.2013.39

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2013 Cancer Research UK

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

PMC Copyright notice

Characteristics of DC immunisation. (A) Tumour growth was monitored in allografted mice immunised on days +7 and +14 (dashed lines) with naïve (DC^naive n=12 and n=8, respectively) and tumour-pulsed DC (DC^neuro2a n=17 and n=16, respectively) as delineated by the arrows. (B) Proliferation of splenic lymphocytes from mice immunised on days +7 (n=9) and +14 (n=5) with tumour-pulsed DC in response to mitogenic stimulation with ConA, and restimulation with tumour-pulsed DC (DC^neuro2a) in vitro. (C) Neuro-2a cell lysis as determined from LDH release by lymphocytes from allografted mice immunised with naïve (antigen-inexperienced) and tumour-pulsed DC on day +7 (n=5) and upon restimulation with tumour-pulsed DC in vitro. Assays were performed at a target:effector ratio of 1 : 50. (D) Tumour size in allografted mice (allo-BMT, n=21), after subcutaneous (SC, n=14) and intravenous (IV, n=11) immunisation with donor DC on day +7 post transplantation.